Asset Details
Do you wish to reserve the book?
The immunosurveillance signature predicts the prognosis and immunotherapy sensitivity for colon adenocarcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The immunosurveillance signature predicts the prognosis and immunotherapy sensitivity for colon adenocarcinoma
Do you wish to request the book?
The immunosurveillance signature predicts the prognosis and immunotherapy sensitivity for colon adenocarcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The immunosurveillance signature predicts the prognosis and immunotherapy sensitivity for colon adenocarcinoma
2025
Overview
Colon adenocarcinoma (COAD) is a leading cause of cancer-related mortality worldwide, with immune escape being a significant factor in the failure of immunotherapy. This study investigates the correlation between Immunosurveillance-related genes and the prognosis of COAD patients, utilizing data from 1140 patients across four public databases: The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), Array-express, and Gene Expression Omnibus (GEO). Employing Cox regression analysis, we identified 182 immune genes significantly linked to overall survival (OS) and established an Immunosurveillance score (ISs) based on 16 of these genes. The ISs score was validated using independent datasets, revealing that patients in the high-ISs group exhibited significantly poorer OS compared to those in the low-ISs group, as demonstrated by Kaplan–Meier curves and Cox regression analyses. Moreover, the ISs score showed a negative correlation with immune scores across multiple datasets. Notably, a higher ISs score was associated with improved recurrence-free survival (RFS) and OS in patients treated with PD-1 and CTLA4 inhibitors. Our findings suggest that the ISs score, derived from Immunosurveillance-related genes, has the potential to serve as a valuable prognostic marker and a tool for identifying COAD patients who may benefit from immunotherapy in clinical settings.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Biomarkers, Tumor - genetics
/ Cancer
/ Colon
/ Colonic Neoplasms - genetics
/ Colonic Neoplasms - immunology
/ Colonic Neoplasms - mortality
/ Female
/ Gene Expression Regulation, Neoplastic
/ Genomes
/ Humanities and Social Sciences
/ Humans
/ Immune checkpoint inhibitors
/ Male
/ Science
/ Survival
